Epidermal growth factor receptor (EGFR) overexpression occurs in a significant percentage of cases of glioblastoma multiforme (GBM), and amplification has been found in approximately 40% of these neoplasms. Controversy exists as to the prognostic significance of EGFR gene amplification: some reports have indicated that amplification is associated with a poor prognosis, while other authors have reported no relationship between gene amplification and prognosis. Some reports have found a poor prognosis to be associated with amplification of the EGFR gene in patients of all ages with GBM, while other authors have found EGFR amplification to be an independent predictor of prolonged survival in patients with GBM who are older than 60 years of age. The authors studied a series of 34 specimens (32 patients) with histologically proven GBM by immunohistochemistry for the presence of EGFR overexpression and by fluorescence in situ hybridization (FISH) for gene amplification of the EGFR gene. Results of these studies and data on patient age, sex, functional status, therapy, and survival were correlated to determine which variables were predictive of survival. p53 expression was also determined by immunohistochemistry and correlated with the other variables and survival.
transmembrane cell surface receptor and a member of the c-erb-B family of tyrosine kinases. These receptors are large proteins found primarily in the cell membranes of epithelial cells. EGFR is known by several names, including ErbB-1 and Her-1. The ligand-binding component of EGFR resides on the exterior surface of the cell and can be activated by hormones, growth factors, neurotransmitters, and other cellular regulators. 1 Following ligand bindings to the EGFR receptor, a series of complex singling pathways are activated resulting in cell proliferation. 2 Normally, EGFR activation is regulated, but when such regulation is disrupted, ongoing stimulation of cell replication results. This deregulation contributes to the development and maintenance of the cancer by initiating continued cell proliferation. Deregulation may result from a number of pathways, including (1) EGFR gene amplification (resulting in more growth factor receptors on a cell surface); (2) increased EGFR transcription or translation (leading to overexpression of mRNA and cell surface growth factor receptors) [3] [4] [5] ; and (3) increased EGFR-mediated signaling, which may also play a part in other regulatory processes, including apoptosis, angiogenesis, and metastatic spread. 6, 7 Because EGFR is associated with regulation of cell proliferation, it has been considered as a possible prognostic marker in human malignancies. EGFR is known to be overexpressed in a variety of human carcinomas, including adenocarcinoma of the colon, non-small cell carcinomas of the lung, and many head and neck carcinomas. [8] [9] [10] Approximately 40% of cases of glioblastoma multiforme show EGFR gene amplification. 11 EGFR protein overexpression is usually associated with gene amplification in examples of glioblastoma multiforme (GBM). EGFR gene amplification status has been studied as a potential prognostic indicator. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] The majority of the early reports showed that amplification of the EGFR gene was associated with a prognosis poorer than that associated with nonamplified GBM. A minority of early studies, 16 and a large meta-analysis of multiple individually recorded studies, 11 failed to confirm this relationship. Subsequent studies have reevaluated this issue, and the majority have found that the relationship between gene amplification and prognosis is age-dependent. In these studies, gene amplification in patients older than 60 years was associated with a relatively favorable prognosis, while in younger patients amplification indicated a poorer prognosis. [17] [18] [19] One study showed that EGFR overexpression was associated with a worse prognosis in younger patients and an improved prognosis in older patients with GBM. 20 Two of the three studies showing a relationship between EGFR gene amplification and GBM prognosis used blotting techniques. 17, 18 The third used fluorescence in situ hybridization (FISH). 19 Because of the potential clinical value of EGFR gene amplification as a prognostic maker for GBM, we studied the prognostic significance of EGFR amplification as determined by FISH analysis using a commercially available FISH probe (Vysis, Downers Grove, IL). We report the results of FISH testing for EGFR in a series of 34 cases of GBM and correlate amplification status with patient survival and other prognostic markers, including p53, patient age, sex, and performance status.
MATERIALS AND METHODS
Following approval of the study by the University of Utah Institutional Review Board, the clinic records of one of the authors (R.L.J.) were reviewed for all patients with a histologic diagnosis of GBM for which long-term clinical follow-up and paraffin block material were available. Thirty-four paraffin-embedded specimens obtained from brain biopsies or tumor resections performed in 32 patients with GBM were retrieved from the files of the Department of Pathology at the University of Utah Health Science Center, Selection of tumor samples was based on morphology and tumor content determined upon review of H&E-stained tissue sections. The mean age of the 32 patients (20 men, 12 women) was 59 years (range 24-85 years). Radiation and chemotherapy were given in 22 patients and radiation alone in 2 patients; 6 patients had neither chemotherapy nor radiation therapy. Demographic data, including patient age and sex, as well as months of survival were obtained from the charts, as was the performance status score (KPS).
Immunohistochemistry
Tissue sections were cut at 4 mm and mounted on Superfrost/Plus microscopic slides (Fisher Scientific, Pittsburgh, PA). The slides were deparaffinized in three washes of xylene for 5 minutes each and then dehydrated in 100%, 95%, and 70% ethanol followed by a wash in distilled water. Slides for p53 staining were subjected to pressure cooker antigen retrieval in citrate buffer. IHC staining was performed using the Nexes instrument (Ventana Inc. Tucson, AZ). The antibodies directed against p53 were obtained from DakoCytomation (Carpinteria, CA) and used at a dilution of 1:80. The p53 antibody was applied to the tissue sections and incubated for 30 minutes. Detection was carried out using Ventana's Basic DAB Detection Kit followed by a hematoxylin counterstain.
IHC staining for EGFR was performed on slides subjected to digestion with Protease II (Ventana) for 16 minutes. The EGFR antibody was used at a dilution of 1:500 and applied to the tissue followed by an incubation of approximately 30 minutes. Detection was carried out using Ventana's Basic DAB Detection Kit followed by a hematoxylin counterstain.
EGFR FISH
Tissue sections for EFGR FISH staining were cut at 4 mm and mounted on Superfrost/Plus microscope slides. The slides were deparaffinized in three washes of xylene for 5 minutes each and then dehydrated in 100% alcohol twice for 2 minutes at each washing. After the slides were allowed to dry, they were placed in the pretreatment solution (Vysis) at 801C for 10 minutes. This was followed by a rinse in purified water for 3 minutes. The slides were digested for 15 minutes in 62.5 mL of 0.2 N HCl containing 250 mg Protease (2,500-3,000 U/mg) (Vysis) and rinsed in purified water for 3 minutes. The slides were then dehydrated through a series of graded ethanol solutions for 1 minute each and allowed to air dry.
Locus-specific EGFR dual-color probes (Vysis), which hybridized to the band region 17pl2 in spectrum orange and the centromere region on chromosome 7 in spectrum green, were applied (8 uL) to each tissue section. A 22 Â 22 coverslip was placed over the probe target area, and the coverslip areas were sealed with rubber cement to prevent evaporation of the probe. Simultaneous denaturing of probe and target was carried out on a Boekel Slide Moat (Boekel Scientific, Feasterville, PA) at 741C for 6 minutes. Hybridization was performed by placing the slides in a humidified chamber at 371C for overnight incubation. After hybridization, rubber cement and coverslips were removed. Slides were treated in a posthybridization wash of 2 Â SSC containing 0.3% NP40 at 731C for 2 minutes and then transferred to ambient temperature 2 Â SSC/0.3% NP40 for 5 to 60 seconds. Slides were air dried and coverslip mounted with DAPI (Vector Labs, Burlingame, CA) nuclear counterstain. The sections were viewed using an Olympus BX41 fluorescent microscope with a dual green/orange filter (Vysis).
Quantification of FISH Slides
For each specimen, 40 intact non-overlapping nuclei were counted for both the green and orange signals. The EGFR/CEP 7 ratio was calculated. Using the criteria developed for the HER-2/neu FISH analysis by Vysis Incorporated, EGFR/CEP 7 ratios of 2 and greater were considered amplified. Ratios less than 2 were considered nonamplified.
IHC Analysis
Slides stained immunohistochemically for EGFR were graded 0 to 3+ (0, no membranous staining; 1+, incomplete noncircumferential IHC satining in Z10% of neoplastic cells; 2+, complete circumferential but weak membrane staining in Z10% of neoplastic cells; 3+, strong circumferential membranous staining in Z10% of neoplastic cells). Stains for p53 were graded as positive or negative using the criteria shown in Table 1 .
Statistical Analysis
The data were analyzed using the Kaplan-Meier and Cox regression analysis techniques. The Cox test was used because it allows analysis of multiple covariates (sex, age, and KPS) that might predict survival and should be included to test whether the factors of interest predict survival even controlling for these other factors. The data were analyzed by Cox regression analysis for the variables EGFR gene amplification by FISH and EGFR expression by IHC The Kaplan-Meier test was used to determine whether EGFR gene amplification as determined by FISH predicted months of survival serially taking into consideration other variables, including sex, age less than 50, age more than 70, and KPS. Table 2 correlates the EGFR gene amplification status with EGFR IHC staining intensity; p53 IHC status; patient age, sex, and KPS; survival in months; and whether the patient received chemotherapy and/or radiation therapy in addition to surgery. Nine cases of GBM showed amplification for the EGFR gene as shown by FISH ( Fig. 1) ; Figure 2 shows a nonamplified case for comparison. Survival in patients with GBMs showing EGFR gene amplification ranged from 3 to 30 months; survival in patients with nonamplified tumors ranged from 1 to 73 months. Five of nine neoplasms with amplification of the EGFR gene had 3+ IHC results for EGFR. Two tumors were associated with 2+ IHC results, and two tumors with amplification of the EGFR gene were associated with no staining for EGFR protein by IHC. Twenty-one of 34 cases showed positive staining for p53 by IHC. There did not appear to be a relation between p53 positivity and EGFR gene amplification status. Table 3 shows the results of Cox regression analysis for prediction of months of survival based on EGFR gene amplification status as determined by FISH. Table 4 shows the Cox regression analysis results for prediction of months of survival by EGFR protein expression determined by IHC. This analysis shows that age significantly predicted months of survival (younger patients survived longer) and performance status significantly predicted months of survival (those with higher performance scores survived longer), but sex and amplification status of EGFR gene by FISH analysis did not predict survival. Similarly, positivity for EGFR protein as shown by IHC did not predict months of survival. All three of these patients had GBMs that were nonamplified by FISH (zero). Table 5 shows the statistical analysis of gene amplification status for EGFR as a predictor of months of survival. Statistical analysis revealed a log-rank statistic of 0.56, with P<0.46. The tests were conducted at each level of the strata (sex, age category, and performance status). The findings did not change with these analyses, and for our data set EGFR gene amplification status did not appear to predict survival. Similarly, Table 6 shows the Kaplan-Meier analysis results for prediction of survival from IHC for EGFR. Again, EGFR protein expression did not appear to predict survival in any of these analyses. Finally, the combination of EGFR gene amplification and protein expression of p53 did not predict survival in our data set.
RESULTS
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DISCUSSION
Analysis of EGFR and the associated gene amplification status has been the focus of considerable research interest. EGFR may represent a target for specific chemotherapy, 21 and gene amplification and/or protein overexpression may represent a prognostic indicator. Several early studies indicated that EGFR gene amplification was associated with a poorer prognosis than nonamplified neoplasms in patients with GBM. [12] [13] [14] [15] Other studies, including a meta-analysis of earlier reports, indicated no prognostic value for EGFR gene amplification. 11, 16 More recent studies of EGFR gene amplification have indicated an age-dependent prognostic value for EGFR gene amplification. Younger patients whose tumors show EGFR amplification have a poorer prognosis than those with nonamplified neoplasms. Patients over 60 years of age have shown a more favorable prognosis when their neoplasms have EGFR gene amplification. [17] [18] [19] [20] Most of the studies indicating a prognostic impact from EGFR gene amplification have used blotting techniques. 17, 18 A single study used FISH to evaluate EGFR gene amplification status on paraffinembedded tissue. 19 In this study, a dual-probe FISH analysis was performed using a commercially available locus-specific probe (Vysis) for EGFR paired with a centromere probe for chromosome 7 (CEP7). 19 Because this methodology is relatively rapid and allows morphologic assessment while amplification status is evaluated, it appears to be a superior methodology for clinical practice. We evaluated a series of 34 cases (32 patients) for EGFR gene amplification status by FISH analysis along with IHC analysis of EGFR protein expression and p53 protein expression. The findings were correlated with patient survival along with co-variables of patient age, sex, performance status, and whether the patient received radiation and/or chemotherapy in addition to surgery. Smith et al 19 used the commercially available Vysis FISH probes for EGFR and CEP7 identical to those used in our study, but the cut-points defining amplification differed. Smith et al defined EGFR amplification as an EGFR/CEP7 ratio of 1.2 or more and that 10% or more of the nuclei had more than three EGFR signals. We used a higher ratio (>2) that corresponds to the cut-point ratio recommended in the procedure for assessment of amplification of HER-2/neu. The HER-2/CEP7 cut-point ratio of 2 or greater has excellent correlation with 3+ IHC staining in our experience. This cut-point appears to be justified from our EGFR FISH and IHC data in that five of nine amplified specimens showed 3+ staining for EGFR by IHC and two additional amplified specimens were associated with 2+ IHC results. Only two specimens determined to be amplified by FISH analysis were associated with lack of staining for EGFR by IHC. Both of these had EGFR/CEP7 ratios of approximately 3. Only two cases had positive results for EGFR protein expression when the EGFR gene was not amplified. Both cases were 2+ by IHC. If the cut-point for amplification was lowered to 1.2 or greater, 13 additional cases would have been considered amplified, but none of these showed overexpression of EGFR protein by IHC (all graded as zero). In addition, including these cases in the analysis of survival would not have changed our prognostic findings, and EGFR gene amplification remained unpredictive of survival.
We used a cut-point of age 70 for testing the prognostic significance of EGFR gene amplification instead of age 60, as used in the study by Smith et al. 19 If we had used the cut-point of age 60 instead of age 70, our results would have been the same. Reanalyzing our data with a cut-point of age 60 failed to show prognostic significance for EGFR gene amplification for patients either above or below age 60.
In our series of 34 samples (32 patients), EGFR gene amplification status was not predictive of either a favorable or unfavorable prognosis. Stratifying our data by sex, age category, and performance status did not alter the inability of EGFR gene amplification or protein expression status to predict outcome in our study. Similarly, p53 expression, alone or in conjunction with EGFR gene amplification status, did not demonstrate predictive value. Varying the age cut-points and EGFR/ CEP7 ratios did not alter our results.
A potential cause far the variability of results seen in the literature and reported here is the known regional heterogeneity of EGFR gene amplification. Nafe et al 22 found distinct regional differences in EGFR gene amplification in two of seven cases they studied. We tried to correct for this variation by counting cells in multiple areas. Nonetheless, GBMs with considerable heterogeneity in amplification status might cloud the relationship between amplification and patient prognosis.
Our findings are similar to the meta-analysis reported by Huncharek and Kupelnick. 11 The patient population in our study was considerably smaller than in the three recent studies showing a correlation between prognosis and EGFR gene amplification status. [17] [18] [19] Sample size may represent a possible explanation for our failure to confirm recent age-dependent results, but our patient populations were otherwise similar. Because determination of EGFR gene amplification status by a commercially available FISH methodology could represent a clinically useful technique for predicting patient survival, additional studies with larger numbers of patients will be needed to establish clinical utility for this test and the presence or absence of a relationship between EGFR gene amplification and patient prognosis.
